X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs CIPLA - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD CIPLA WYETH LTD/
CIPLA
 
P/E (TTM) x 27.7 44.1 62.9% View Chart
P/BV x 5.3 3.6 147.3% View Chart
Dividend Yield % 1.3 0.4 360.3%  

Financials

 WYETH LTD   CIPLA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
CIPLA
Mar-17
WYETH LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,044622 167.9%   
Low Rs818458 178.5%   
Sales per share (Unadj.) Rs298.6181.9 164.2%  
Earnings per share (Unadj.) Rs57.212.9 444.8%  
Cash flow per share (Unadj.) Rs58.429.3 199.3%  
Dividends per share (Unadj.) Rs17.002.00 850.0%  
Dividend yield (eoy) %1.80.4 493.0%  
Book value per share (Unadj.) Rs249.5155.7 160.2%  
Shares outstanding (eoy) m22.72804.51 2.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.13.0 105.0%   
Avg P/E ratio x16.342.0 38.8%  
P/CF ratio (eoy) x15.918.4 86.5%  
Price / Book Value ratio x3.73.5 107.6%  
Dividend payout %29.715.5 191.1%   
Avg Mkt Cap Rs m21,157434,516 4.9%   
No. of employees `0000.523.0 2.1%   
Total wages/salary Rs m40026,338 1.5%   
Avg. sales/employee Rs Th13,787.46,349.1 217.2%   
Avg. wages/employee Rs Th813.01,143.0 71.1%   
Avg. net profit/employee Rs Th2,643.3449.3 588.3%   
INCOME DATA
Net Sales Rs m6,783146,302 4.6%  
Other income Rs m3532,287 15.4%   
Total revenues Rs m7,136148,589 4.8%   
Gross profit Rs m1,61724,758 6.5%  
Depreciation Rs m2713,229 0.2%   
Interest Rs m61,594 0.3%   
Profit before tax Rs m1,93812,222 15.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6321,798 35.2%   
Profit after tax Rs m1,30110,354 12.6%  
Gross profit margin %23.816.9 140.9%  
Effective tax rate %32.614.7 221.8%   
Net profit margin %19.27.1 270.9%  
BALANCE SHEET DATA
Current assets Rs m6,98487,370 8.0%   
Current liabilities Rs m2,05633,081 6.2%   
Net working cap to sales %72.637.1 195.8%  
Current ratio x3.42.6 128.6%  
Inventory Days Days9987 114.1%  
Debtors Days Days2462 38.4%  
Net fixed assets Rs m244111,567 0.2%   
Share capital Rs m2271,609 14.1%   
"Free" reserves Rs m5,441123,645 4.4%   
Net worth Rs m5,668125,254 4.5%   
Long term debt Rs m2536,454 0.1%   
Total assets Rs m7,901209,532 3.8%  
Interest coverage x353.38.7 4,076.1%   
Debt to equity ratio x00.3 1.5%  
Sales to assets ratio x0.90.7 123.0%   
Return on assets %16.55.7 289.9%  
Return on equity %22.98.3 277.6%  
Return on capital %34.08.5 400.5%  
Exports to sales %0.234.2 0.6%   
Imports to sales %36.38.3 435.7%   
Exports (fob) Rs m1550,050 0.0%   
Imports (cif) Rs m2,46512,203 20.2%   
Fx inflow Rs m1551,066 0.0%   
Fx outflow Rs m2,67717,678 15.1%   
Net fx Rs m-2,66233,388 -8.0%   
CASH FLOW
From Operations Rs m92323,824 3.9%  
From Investments Rs m317-13,127 -2.4%  
From Financial Activity Rs m-481-13,239 3.6%  
Net Cashflow Rs m759-2,478 -30.6%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 51.1 20.8 245.7%  
Indian inst/Mut Fund % 11.3 12.2 92.6%  
FIIs % 7.2 23.7 30.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 30.4 26.2 116.0%  
Shareholders   21,978 161,166 13.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  SHASUN PHARMA  GSK PHARMA  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WYETH LTD WITH

MARKET STATS